This deal removes geographic fragmentation and unlocks full global optionality for felzartamab, which is in late-stage trials for multiple high-unmet-need immune diseases. Given China's large patient pool for IgAN and PMN, the market opportunity is substantial. Monitor upcoming Phase 3 readouts as key catalysts for valuation expansion.
Price Chart
Executive Summary
Biogen has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma, consolidating full global rights to the CD38-directed antibody. The deal includes a $100 million upfront payment and up to $750 million in potential milestone payments, plus tiered royalties on future sales in China.
Key Financial Metrics
Key Facts
- Biogen acquires exclusive Greater China rights to felzartamab from TJ Biopharma
- Total potential deal value: up to $850 million ($100M upfront, $750M in milestones)
- Biogen now holds full worldwide rights to felzartamab, a potential pipeline-in-a-product for immune-mediated diseases
- Felzartamab is in global Phase 3 trials for IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and kidney transplant rejection
- China has one of the largest patient populations globally for IgAN and PMN, representing a major commercial opportunity
- Biogen will lead development, manufacturing, and commercialization in China; TJ Bio to manufacture for multiple myeloma indication
Financial Impact
$100 million upfront expense in Q2 2026; potential additional $750 million in milestone payments tied to commercial success
Risk Factors
- Felzartamab remains investigational with no regulatory approvals yet; clinical trial results may not meet endpoints
- Milestone payments are contingent on commercial success, which depends on regulatory approval and market adoption
- Increased R&D expense from upfront $100M charge may pressure near-term earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access